2013
DOI: 10.1016/j.oraloncology.2012.06.017
|View full text |Cite
|
Sign up to set email alerts
|

Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
31
0
11

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 37 publications
(42 citation statements)
references
References 27 publications
0
31
0
11
Order By: Relevance
“…Moreover, podoplanin highly influences the expression of matrix metalloproteinase‐9, which is believed to play a key role in processes requiring basal membrane disruption, such as tumor invasion . Recent experimental data also demonstrated that the epidermal growth factor and the transforming growth‐factor beta promote podoplanin expression in oral squamous cell carcinoma . The phenotypic effects of transforming growth‐factor beta expression in advanced cancer stages include the induction of epithelial to mesenchymal transition and the activation of cancer‐associated fibroblasts together with the promotion of an intense fibrotic remodeling of the extracellular matrix .…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, podoplanin highly influences the expression of matrix metalloproteinase‐9, which is believed to play a key role in processes requiring basal membrane disruption, such as tumor invasion . Recent experimental data also demonstrated that the epidermal growth factor and the transforming growth‐factor beta promote podoplanin expression in oral squamous cell carcinoma . The phenotypic effects of transforming growth‐factor beta expression in advanced cancer stages include the induction of epithelial to mesenchymal transition and the activation of cancer‐associated fibroblasts together with the promotion of an intense fibrotic remodeling of the extracellular matrix .…”
Section: Discussionmentioning
confidence: 99%
“…Podoplanin is a transmembrane glycoprotein expressed in a variety of normal and neoplastic tissues which among other features can promote invasion through interaction with intra‐ and extracellular elements such as actin and various growth factors, respectively. TGF‐β is a multifunctional polypeptide involved in a variety of actions including the induction of different factors which is performed through its type I and II receptors by phosphorylation of receptor‐activated‐Smads (R‐Smads) that bind to a common (co‐)Smad and translocate into the nucleus, to regulate the expression of multiple target genes …”
Section: Discussionmentioning
confidence: 99%
“…Podoplanin affects various processes and can be influenced by numerous factors within the cell or surrounding connective tissue; for example, molecules such as interferon‐gamma, Ki‐67, basic fibroblast growth factor, tumor necrosis factor‐alpha and interleukins 6 and 22 have been evaluated in relation to podoplanin, but the regulatory mechanisms involved in its expression have not been fully explored . Transforming growth factor‐β (TGF‐β) superfamily is a large group of related proteins involved in a variety of cellular and intercellular processes with the ability to modify and regulate numerous, and at times, contradictory events including induction of apoptosis, epithelial‐mesenchymal transition and mitogenic signals, inhibition of proliferation and regulation of angiogenesis and has also been shown to induce podoplanin in some, but not all, cells …”
Section: Introductionmentioning
confidence: 99%
“…Over 3 mM, increased p21 expression and cell cycle G2/M phase arrest were observed. NaBu regulated the expression of rate‐limiting enzymes, augmented the synthesis of prostaglandin E2 (Miki et al, ), and decreased the small membrane glycoprotein podoplanin level partly via suppression of differentiation maker KRT10 (Ohta et al, ). The anti‐cancer activity was also driven by BMI1 depletion (Li, Wang, et al, ).…”
Section: Histone Modifications As Therapeutic Targetsmentioning
confidence: 99%